Huaixiang HAO;Rou-Fun KWONG;Feng CONG;Ann TAYLOR;Yang XIE;Lloyd B. KLICKSTEIN
发明人:
Feng CONG,Huaixiang HAO,Lloyd B. KLICKSTEIN,Rou-Fun KWONG,Ann TAYLOR,Yang XIE
申请号：
US15073156
公开号：
US20180066067A1
申请日:
2016.03.17
申请国别(地区):
US
年份:
2018
代理人:
摘要：
The transmembrane E3 ubiquitin ligases ZNRF3 and RNF43 are negative regulators of β-catenin and the Wnt signaling pathway in eukaryotic cells. The activity of ZNRF3 can be modulated by antibody binding to its extracellular domain, thus causing an increase in Wnt signaling. The ZNRF3 antagonizing antibodies can be used to treat diseases with low Wnt signaling, such as short bowel syndrome, osteoporosis, diabetes, neurodegenerative diseases, and mucositis. In addition, the antagonizing antibodies of the invention can be used to enhance Wnt signaling for tissue repair and wound healing.
